Danaher DHR Life Sciences, Biotechnology and Diagnostics Segment — Impairment Charges
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Danaher in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: Danaher’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:36 PM EST
- Fiscal year
- FY2025
- Accession
- 0000313616-26-000062
Additionally, during 2025, the Company identified impairment triggers for certain long-lived technology assets, a trade name and other assets in the Biotechnology, Life Sciences and Diagnostics segments. During the year ended December 31, 2025, the Company recorded impairment charges of $130 million related to these long-lived assets. During 2024, the Company identified impairment triggers for a trade name in the Diagnostics segment and recorded an impairment charge of $43 million in the year ended December 31, 2024. The Company identified impairment triggers in 2023 in the Diagnostics and Biotechnology segments which resulted in impairment charges for certain long-lived assets, including technology and other assets totaling $77 million. The 2025, 2024 and 2023 impairment charges were recorded in SG&A expenses in the accompanying Consolidated Statements of Earnings, except for $29 million and $14 million in 2025 and 2023, respectively, which were recorded in cost of sales in the accompanying Consolidated Statements of Earnings.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Danaher's life sciences, biotechnology and diagnostics segment — impairment charges?
- Danaher (DHR) reported life sciences, biotechnology and diagnostics segment — impairment charges of $32.5M in Q4 2025.
- What does life sciences, biotechnology and diagnostics segment — impairment charges mean?
- This metric represents the non-cash expense recognized when the carrying value of long-lived assets, such as goodwill, intangible assets, or property, plant, and equipment, within the life sciences and diagnostics segment exceeds their fair market value. It serves as a critical indicator of potential overvaluation of past acquisitions or a decline in the long-term economic viability of specific product lines or technologies within the segment. Monitoring these charges helps investors assess the quality of capital allocation and the accuracy of historical investment valuations.
Ask your AI about Danaher's life sciences, biotechnology and diagnostics segment — impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
